

GLOBAL
PHARMACEUTICAL
COMPANY

Investor Meeting

THE GLOBAL LEADER IN RARE DISEASES

INVESTOR DAY



3 DRUGS approved for devastating rare diseases	4 ULTRA-RARE DISEASES Breakthrough innovations treating	6 POTENTIAL NEW PRODUCTS or indication approvals through 2018
Serving patients in 50 COUNTRIES	with 3,000 TALENTED COLLEAGUES	
39% ANNUALIZED TSR	2 FDA RARE PEDIATRIC DISEASE Priority review vouchers	10 PROGRAMS in clinical development
	30 PROGRAMS in our pre-clinical rare disease pipeline	

Our Strategic Criteria for Internal and External Growth

Patients Are at the Center of Everything We Do

Our Mission:
developing life-transforming treatments for patients with devastating and rare diseases

A global pharmaceutical conducted its first Investor Day and turned to Broadstreet to ensure the event was exceptional.

Current state of the business and well as a thorough review of the robust pipeline was presented by a series of executives with cutting edge visual graphics, animation and video.

In addition to the visual elements of the presentations, the entire environment was designed to provide attendees with critical information in the most clear and effective manner.

The event produced over 100 unique articles, all favorable and the design format has become the basis for all corporate communications.